Opus Genetics
IRD----
Opus Genetics (IRD)
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited reti...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Opus Genetics Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$10.56224.29%
Forecast & RatingStrong buy
18analysts
- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 20 at 05:03 AM
Top 3 Health Care Stocks That May Rocket Higher In July
- Tip Ranks · Jul 10 at 06:36 AM
Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)
- Tip Ranks · Jul 9 at 09:55 AM
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
- PUBT · Jul 9 at 06:01 AM
Opus Genetics to release 3-month Cohort 1 topline data for OPGx-BEST1 trial in September 2026
- Tip Ranks · Jul 6 at 12:15 PM
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
- PUBT · Jul 6 at 06:02 AM
Opus Genetics posts press release on FDA alignment for OPGx-LCA5 Phase 3 trial design
